NASDAQ:INSMInsmed Stock Price, Forecast & News

Insmed's stock was trading at $21.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INSM stock has increased by 27.8% and is now trading at $27.15.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Insmed.

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Insmed.

Insmed will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.72) by $0.02. The biopharmaceutical company had revenue of $36.90 million for the quarter, compared to analyst estimates of $34.81 million. Insmed had a negative net margin of 162.82% and a negative return on equity of 87.35%. Insmed's quarterly revenue was up 68.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.96) earnings per share.
View Insmed's earnings history.

8 Wall Street analysts have issued 12-month target prices for Insmed's stock. Their forecasts range from $20.00 to $56.00. On average, they expect Insmed's stock price to reach $42.00 in the next year. This suggests a possible upside of 54.7% from the stock's current price.
View analysts' price targets for Insmed.

News stories about INSM stock have trended somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Insmed earned a news impact score of 1.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Insmed.

Some companies that are related to Insmed include Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Perrigo (PRGO), Bausch Health Companies (BHC), ACADIA Pharmaceuticals (ACAD), Jazz Pharmaceuticals (JAZZ), Emergent Biosolutions (EBS), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA) and Ultragenyx Pharmaceutical (RARE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Geron (GERN), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Opko Health (OPK) and Amarin (AMRN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by many different institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.29%), Frontier Capital Management Co. LLC (0.27%), Scout Investments Inc. (0.23%), First Trust Advisors LP (0.04%), ProShare Advisors LLC (0.03%) and SG Americas Securities LLC (0.02%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis.
View institutional ownership trends for Insmed.

INSM stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC.
View insider buying and selling activity for Insmed.

INSM stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Frontier Capital Management Co. LLC, Scout Investments Inc., First Trust Advisors LP, ProShare Advisors LLC, Strs Ohio, Dupont Capital Management Corp, and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen, and William Lewis.
View insider buying and selling activity for Insmed.

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INSM stock can currently be purchased for approximately $27.15.

Insmed has a market capitalization of $2.74 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe.

The official website for Insmed is www.insmed.com.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]